Thromboplastin reagents

Details Thromboplastin reagents Thromboplastin reagents

2006-12-12

2006-12-12

Wallenhorst, Maureen M. (Department: 1743)

Chemistry: analytical and immunological testing

Clotting or clotting factor level tests

C436S008000, C436S016000, C436S018000, C252S408100

Reexamination Certificate

active

07148067

ABSTRACT:
A thromboplastin reagent includes tissue factor, Factor VIIa, and a net negatively charged phospholipid. The thromboplastin reagent is a synthetic thromboplastin reagent, and is in dried form.

REFERENCES:
patent: 3983004 (1976-09-01), Trobisch et al.
patent: 4139619 (1979-02-01), Chidsey, III
patent: 4416812 (1983-11-01), Becker et al.
patent: 4684635 (1987-08-01), Orentreich et al.
patent: 4784944 (1988-11-01), Kolde
patent: 5059525 (1991-10-01), Bartl et al.
patent: 5169786 (1992-12-01), Carroll et al.
patent: 5192689 (1993-03-01), Hemker et al.
patent: 5254350 (1993-10-01), Barrow et al.
patent: 5270451 (1993-12-01), Hawkins et al.
patent: 5298599 (1994-03-01), Rezaie et al.
patent: 5314695 (1994-05-01), Brown
patent: 5338538 (1994-08-01), Tricca et al.
patent: 5358853 (1994-10-01), Butler et al.
patent: 5391380 (1995-02-01), Barrow et al.
patent: 5418141 (1995-05-01), Zweig et al.
patent: 5418143 (1995-05-01), Zweig
patent: 5426031 (1995-06-01), Hawkins et al.
patent: 5504067 (1996-04-01), Morrissey et al.
patent: 5504193 (1996-04-01), Hawkins et al.
patent: 5508170 (1996-04-01), Butler et al.
patent: 5512304 (1996-04-01), Barrow et al.
patent: 5580744 (1996-12-01), Zweig
patent: 5599909 (1997-02-01), Fickenscher et al.
patent: 5625036 (1997-04-01), Hawkins et al.
patent: 5691380 (1997-11-01), Mason et al.
patent: 5741658 (1998-04-01), Morrissey
patent: 5866425 (1999-02-01), Woodhams et al.
patent: 5888968 (1999-03-01), Chen et al.
patent: 5945087 (1999-08-01), Nelson et al.
patent: 5968528 (1999-10-01), Deckner et al.
patent: 6100072 (2000-08-01), Brucato et al.
patent: 6194394 (2001-02-01), Hawkins
patent: 6248353 (2001-06-01), Singh
patent: 6261803 (2001-07-01), Zander et al.
patent: 6319896 (2001-11-01), Dorin et al.
patent: 6323326 (2001-11-01), Dorin et al.
patent: 6376209 (2002-04-01), Wissel et al.
patent: 6391609 (2002-05-01), Goldford
patent: 6432657 (2002-08-01), Kikuchi et al.
patent: 6528273 (2003-03-01), Hawkins
patent: 6706861 (2004-03-01), Singh et al.
patent: 6733985 (2004-05-01), Lee
patent: 6815424 (2004-11-01), Vickery et al.
patent: 2001/0004641 (2001-06-01), Hawkins
patent: 2002/0012699 (2002-01-01), Singh et al.
patent: 2002/0012958 (2002-01-01), Wissel et al.
patent: 2002/0019021 (2002-02-01), Kraus
patent: 2002/0132370 (2002-09-01), Lassen et al.
patent: 2002/0151646 (2002-10-01), Kikukawa et al.
patent: 2002/0182225 (2002-12-01), Wang et al.
patent: 2003/0064414 (2003-04-01), Benecky et al.
patent: 2003/0153084 (2003-08-01), Zheng et al.
patent: 2003/0211460 (2003-11-01), Nelsesluen
patent: 2004/0037893 (2004-02-01), Hansen et al.
patent: 2004/0043933 (2004-03-01), Hansen et al.
patent: 2004/0084867 (2004-05-01), Leyland-Jones
patent: 2004/0086953 (2004-05-01), Jenny et al.
patent: 0 727 434 (1996-08-01), None
patent: 0 942 284 (1999-09-01), None
patent: WO 93/07492 (1993-04-01), None
patent: WO 98/44352 (1998-10-01), None
patent: WO 00/62742 (2000-10-01), None
Bader R, Mannucci PM, Tripodi A, Hirsh J, Keller F, Solleder EM, Hawkins P, Peng M, Pelzer H, Teijidor LM, et al. Multicentric evaluation of a new PT reagent based on recombinant human tissue factor and synthetic phospholipids. Thromb Haemost 1994; 71:292-299.
Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003: 107: 1692-1711.
Hoots, K., Disseminated Intravacular Coagulation (DIC) Minutes from Jun. 18, 2004 meeting, pp. 1-6.
Jackson C. Monitoring Oral Anticoagulant Therapy—INR values for the Owren Prothrombin Time, Hemosaga Diagnostics Corporation, San Dieto, CA, Dec. 5, 2003, Thromb Haemost 2004; 91: 210-212.
Kemball-Cook G, Gamer I, Imanaka Y, Nishimura T, O'Brien DP, Tuddenham EG, McVey JH. High-level production of human blood coagulation factors VII and XI using a new mammalian expression vector. Gene. Feb. 25, 1994;139(2):275-279.
Kitchen S, Jennings I, Woods TA, Walker ID, Preston FE. Two recombinant tissue factor reagents compared to conventional thromboplastins for determination of international normalised ratio: a thirty-three-laboratory collaborative study. The Steering Committee of the UK National External Quality Assessment Scheme for Blood Coagulation. Thromb Haemost 1996: 76:372-376.
Kitchen S, Preston FE. Standardization of prothrombin time for laboratory control of oral anticoagulant therapy. Semin Thromb Hemost 1999; 25:17-25.
Massignon D, Moulsma M, Bondon P, Debize G, Abidi H, Buttin T, Bon C, Pilllonchery G, Coeur P. Prothrombin time sensitivity and specificity to mild clotting factor deficiencies of the extrinsis pathway: evaluation of eight commercial thromboplastins. Thromb Haemost 1996; 75:590-594.
Morrison M., Caldwell A., McQuacker G., Fitzsimons EJ., Discrepant INR values: a comparison between Manchester and Thrombotest reagents using capillary and venous samples. Clin Lab Haematol 1989; 11(4):393-398.
Morrissey JH, Fakhrai H, Edgington TS. Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade. Cell 1987; 50:129-135.
Morrissey JH. Tissue factor: an enzyme cofactor and a true receptor. Thromb Haemost 2001; 86:66-74.
Neuenschwander PF, Bianco-Fisher E, Rezale AR, Morrissey JH. Phosphatidylethanolamine augments factor Villa-tissue factor activity: enhancement of sensitivity to phosphatidylserine. Biochemistry 1995; 34:13988-13993.
Poller L, Barrowcliffe TW, Van Den Besselaar AM, Jespersen J, Tripodi A, Houghton D. Minimum lyophilized plasma requirement for ISI calibration. European Concerted Action on Anticoagulation. Am J Clin Pathol 1998; 109:196-204.
Poller L. International Normalized Ratios (INR): the first 20 years. J. Thromb Haemost. Jun. 2004;2(6):849-60.
Rezaie AR, Fiore MM, Neuenschwander PF, Esmon CT, Morrissey JH. Expression and purificationof a soluble tissue factor fusion protein with an epitope for an unusual calcium-dependent antibody. Protein Expr Purif 1992; 3:453-460.
Roussi J, Drouet L, Samama M, Sie P. French multicentric evaluationof recombinant tissue factor (recombiplastin) for determination of prothrombin time. Thromb Haemost 1994; 72:698-704.
Search for USPTO website dated May 26, 2004, for key words “Factor VII” AND thromboplastin.
Search from USPTO website dated May 27, 2004, for key words “Factor VII” AND thromboplastin, PGPUB Production Database.
Smith SA, Morrissey JH. Rapid and efficient incorporation of tissue factor into liposomes, J Thromb Haemost 2004; 2:1155-1162. (provided as a preprint of the paper).
Testa S, Morstabilini G, Fattorini A, Galli L, Denti N, D'Angelo A. Discrepant sensitivity of thromboplastin reagents to clotting factor levels explored by the prothrombin time in patients on stable oral anticoagulant treatment: impact on the international normalized ration system. Haematologica 2002; 87:1265-1273.
Van Den Besselaar AM, Tripodi A, Poller L. WHO guidelines for thromboplastins and plasma used to control oral anticoagulation therapy. Annex 3. World Health Organ Tech Rep Ser 1999; 889: 64-93.
Watson C, Kitchen S, Woolley AM, Young L, Malia RG. Recombinant and tissue extract thromboplastins for determination of international normalised ration in over-anticoagulated patients. Br J Biomed Sci 1999; 56:123-127.
Zwaal RF. Membrane and lipid involvement in blood coagulation. Biochim Biophys Acta 1978; 515:163-205.
Abstract of: Smith, S.A., et al., “Do elevated plasma tissue factor pathway inhibitor (TFPI) levels affect measurement of factor Vlla?”., Blood, vol. 104, issue 11, (2004).
Abstract of: Smith, S.A., et al., “Polyphosphates—A novel modulator of coagulation”., Artheriosclerosis, Thrombosis, and Vascular Biology, Journal of the American Heart Association, Abstracts of the 6thAnnual Conference on arteriosclerosis, Thrombosis and Vascular Biology, vol. 25, 4 pages, (2005).
Bouma, B.N., et al., Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U(., Journal of Thrombosis and Haemostasis, vol. 1, pp. 1566-1574

Affiliated with

Also associated with

Rating

Thromboplastin reagents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Thromboplastin reagents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thromboplastin reagents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3663802